Protalix BioTherapeutics (NYSEMKT: PLX)
Protalix BioTherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Protalix BioTherapeutics Company Info
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.
News & Analysis
Why Protalix BioTherapeutics Stock Is Plunging Today
Investors did not like the company's latest regulatory update.
The Simplest Biotech Growth Portfolio Ever
Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.
Is This Orphan Drugmaker in Trouble?
Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?
Can Protalix Revolutionize This Orphan Disease?
The latest results in Protalix's pipeline may be from a phase 1 trial, but don't let that fool you. If successful, PRX-112 could run laps around Shire and Sanofi and catch the attention of larger partners, including Pfizer.
Should You Buy Protalix for Its Platform Alone?
Does disruptive potential trump poor finances for this developmental-stage company?
How Far Can $69 Million Take Protalix?
A debt offering sent shares south. How far can the extra cash take this biotech?
5 of Last Week's Biggest Losers
These five stocks posted double-digit declines this past week.
American Generics Can't Touch This $8 Billion Drug (Yet)
A quirk in patent laws handed Enbrel exclusivity through 2028, but the competition isn't wasting any time.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.